Replimune (REPL) Amortization of Deferred Charges (2024 - 2026)
Replimune (REPL) reported Amortization of Deferred Charges of $201000.0 for Q1 2026, up 13.56% on a YoY basis from $177000.0 in Q1 2025, and up 3.61% sequentially from $194000.0 in Q4 2025.
Replimune (REPL) Amortization of Deferred Charges (2024 - 2026) Analysis & Trends
Replimune (REPL) has 3 years of Amortization of Deferred Charges data on file, last reported at $201000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges rose 13.56% year-over-year to $201000.0; the trailing twelve-month figure through Mar 2026 stood at $771000.0 (up 12.88% YoY), and the FY2026 full-year result was $771000.0, up 12.88% from the prior year.
- Amortization of Deferred Charges grew to $201000.0 in Q1 2026, from $194000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $201000.0 in Q1 2026 to a low of $164000.0 in Q2 2024.
- A 3-year average of $181750.0 and a median of $181000.0 in 2025 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges climbed 12.14% in 2025 and increased 13.56% in 2026, its largest moves.
- Tracing REPL's Amortization of Deferred Charges over 3 years: stood at $173000.0 in 2024, then rose by 12.14% to $194000.0 in 2025, then advanced by 3.61% to $201000.0 in 2026.
- Business Quant data shows REPL's Amortization of Deferred Charges at $201000.0 in Q1 2026, $194000.0 in Q4 2025, and $191000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 201,000.00 |
| Mar 31, 2026 | 201,000.00 |
| Dec 31, 2025 | 194,000.00 |
| Dec 31, 2025 | 194,000.00 |
| Sep 30, 2025 | 191,000.00 |
| Sep 30, 2025 | 191,000.00 |
| Jun 30, 2025 | 185,000.00 |
| Jun 30, 2025 | 185,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Dec 31, 2024 | 173,000.00 |
| Dec 31, 2024 | 173,000.00 |
| Sep 30, 2024 | 169,000.00 |
| Sep 30, 2024 | 169,000.00 |
| Jun 30, 2024 | 164,000.00 |
| Jun 30, 2024 | 164,000.00 |